AKT1 and prostate cancer: AZD5363, an inhibitor of all isoforms of Akt, has been reported to inhibit proliferation and induce apoptosis in prostate cancer cell lines expressing AR and has antitumor activity in vivo in androgen-sensitive LNCaP xenograft models resistant to castration [119].